Results 201 to 210 of about 12,515 (211)
Some of the next articles are maybe not open access.
Spotlight on Imatinib Mesylate in Chronic Myeloid Leukemia1
BioDrugs, 2004Imatinib mesylate (Gleevec, Glivec) is an orally administered competitive inhibitor of the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukemia (CML). In patients with newly diagnosed and previously untreated (apart from hydroxyurea and/or anagrelide) CML in the chronic phase, imatinib mesylate 400 mg/day ...
Katherine F Croom +2 more
openaire +3 more sources
Epigenetic Silencing and Resistance to Imatinib Mesylate in CML [PDF]
, 2004 Abstract : Resistance to Imatinib mesylate is emerging as a real clinical problem in the management of chronic myelogenous leukemia (CML). In this project, we are exploring the hypothesis that epigenetic silencing associated with promoter DNA methylation mediates resistance in selected cases, and that reversal of silencing by decitabine-induced ...
openaire +1 more source
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2007Mark W.M. Schellings +2 more
openaire +3 more sources
Pneumatosis intestinalis and imatinib mesylate
Annals of Hematology, 2014Fiona McElligott +4 more
openaire +2 more sources
The new era of imatinib mesylate
Leukemia Research, 2004Kazuma Ohyashiki, John M. Goldman
openaire +2 more sources
Pseudoporphyria induced by imatinib mesylate
International Journal of Dermatology, 2013Nerea Ormaechea Pérez +4 more
openaire +2 more sources
Hypopigmentation from Imatinib Mesylate (Gleevec)
Journal of Pediatric Hematology/Oncology, 2004William Grossman, David B. Wilson
openaire +3 more sources
Imatinib mesylate–induced pseudoporphyria
Journal of the American Academy of Dermatology, 2010Joseph C. English, Adar T. Berghoff
openaire +2 more sources